FGFR2 and gastric cancer: Combination of FGFR inhibitors with EGFR or MAPK pathway inhibitors can also be considered given that FGFR inhibitor AZD4547 has synergic activity with EGFR inhibitor cetuximab in gastric cancer cells with FGFR2 amplifications [161].